vs
Amphastar Pharmaceuticals, Inc.（AMPH）与TG THERAPEUTICS, INC.（TGTX）财务数据对比。点击上方公司名可切换其他公司
TG THERAPEUTICS, INC.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$192.6M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 12.0%，领先1.4%），TG THERAPEUTICS, INC.同比增速更快（78.0% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $19.6M），过去两年TG THERAPEUTICS, INC.的营收复合增速更高（74.2% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
TG Therapeutics是一家处于商业化阶段的生物制药企业，专注于开发及商业化B细胞恶性肿瘤、自身免疫性疾病与神经退行性疾病的创新疗法，核心产品线覆盖靶向单克隆抗体与口服小分子药物，主要市场为北美和欧洲。
AMPH vs TGTX — 直观对比
营收规模更大
TGTX
是对方的1.1倍
$183.1M
营收增速更快
TGTX
高出79.8%
-1.8%
净利率更高
AMPH
高出1.4%
12.0%
自由现金流更多
AMPH
多$5.0M
$19.6M
两年增速更快
TGTX
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $192.6M |
| 净利润 | $24.4M | $23.0M |
| 毛利率 | 46.8% | 80.2% |
| 营业利润率 | 19.4% | 26.2% |
| 净利率 | 13.3% | 12.0% |
| 营收同比 | -1.8% | 78.0% |
| 净利润同比 | -35.7% | -1.3% |
| 每股收益（稀释后） | $0.51 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHTGTX
| Q4 25 | $183.1M | $192.6M | ||
| Q3 25 | $191.8M | $161.7M | ||
| Q2 25 | $174.4M | $141.1M | ||
| Q1 25 | $170.5M | $120.9M | ||
| Q4 24 | $186.5M | $108.2M | ||
| Q3 24 | $191.2M | $83.9M | ||
| Q2 24 | $182.4M | $73.5M | ||
| Q1 24 | $171.8M | $63.5M |
净利润AMPHTGTX
| Q4 25 | $24.4M | $23.0M | ||
| Q3 25 | $17.4M | $390.9M | ||
| Q2 25 | $31.0M | $28.2M | ||
| Q1 25 | $25.3M | $5.1M | ||
| Q4 24 | $38.0M | $23.3M | ||
| Q3 24 | $40.4M | $3.9M | ||
| Q2 24 | $37.9M | $6.9M | ||
| Q1 24 | $43.2M | $-10.7M |
毛利率AMPHTGTX
| Q4 25 | 46.8% | 80.2% | ||
| Q3 25 | 51.4% | 82.6% | ||
| Q2 25 | 49.6% | 86.6% | ||
| Q1 25 | 50.0% | 87.1% | ||
| Q4 24 | 46.5% | 85.8% | ||
| Q3 24 | 53.3% | 88.9% | ||
| Q2 24 | 52.2% | 88.7% | ||
| Q1 24 | 52.4% | 91.4% |
营业利润率AMPHTGTX
| Q4 25 | 19.4% | 26.2% | ||
| Q3 25 | 13.2% | 18.2% | ||
| Q2 25 | 24.2% | 24.7% | ||
| Q1 25 | 21.9% | 7.1% | ||
| Q4 24 | 24.2% | 27.7% | ||
| Q3 24 | 29.8% | 14.8% | ||
| Q2 24 | 30.3% | 12.0% | ||
| Q1 24 | 27.9% | -14.6% |
净利率AMPHTGTX
| Q4 25 | 13.3% | 12.0% | ||
| Q3 25 | 9.0% | 241.7% | ||
| Q2 25 | 17.8% | 20.0% | ||
| Q1 25 | 14.8% | 4.2% | ||
| Q4 24 | 20.4% | 21.6% | ||
| Q3 24 | 21.1% | 4.6% | ||
| Q2 24 | 20.8% | 9.4% | ||
| Q1 24 | 25.1% | -16.9% |
每股收益（稀释后）AMPHTGTX
| Q4 25 | $0.51 | $0.14 | ||
| Q3 25 | $0.37 | $2.43 | ||
| Q2 25 | $0.64 | $0.17 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.16 | ||
| Q3 24 | $0.78 | $0.02 | ||
| Q2 24 | $0.73 | $0.04 | ||
| Q1 24 | $0.81 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $142.0M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $648.0M |
| 总资产 | $1.6B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHTGTX
| Q4 25 | $282.8M | $142.0M | ||
| Q3 25 | $276.2M | $131.6M | ||
| Q2 25 | $231.8M | $251.9M | ||
| Q1 25 | $236.9M | $276.2M | ||
| Q4 24 | $221.6M | $311.0M | ||
| Q3 24 | $250.5M | $341.0M | ||
| Q2 24 | $217.8M | $217.3M | ||
| Q1 24 | $289.6M | $209.8M |
总债务AMPHTGTX
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHTGTX
| Q4 25 | $788.8M | $648.0M | ||
| Q3 25 | $776.7M | $607.2M | ||
| Q2 25 | $757.5M | $276.4M | ||
| Q1 25 | $751.3M | $237.3M | ||
| Q4 24 | $732.3M | $222.4M | ||
| Q3 24 | $727.7M | $192.2M | ||
| Q2 24 | $713.3M | $177.6M | ||
| Q1 24 | $672.4M | $160.1M |
总资产AMPHTGTX
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.6B | $702.6M | ||
| Q1 25 | $1.6B | $656.7M | ||
| Q4 24 | $1.6B | $577.7M | ||
| Q3 24 | $1.5B | $586.0M | ||
| Q2 24 | $1.5B | $401.2M | ||
| Q1 24 | $1.6B | $373.3M |
负债/权益比AMPHTGTX
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $19.7M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $19.6M |
| 自由现金流率自由现金流/营收 | 13.4% | 10.2% |
| 资本支出强度资本支出/营收 | 4.5% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.35× | 0.85× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-25.0M |
8季度趋势，按日历期对齐
经营现金流AMPHTGTX
| Q4 25 | $32.9M | $19.7M | ||
| Q3 25 | $52.6M | $-23.2M | ||
| Q2 25 | $35.6M | $7.4M | ||
| Q1 25 | $35.1M | $-28.7M | ||
| Q4 24 | $29.0M | $-25.6M | ||
| Q3 24 | $60.0M | $-12.2M | ||
| Q2 24 | $69.1M | $5.5M | ||
| Q1 24 | $55.3M | $-8.2M |
自由现金流AMPHTGTX
| Q4 25 | $24.6M | $19.6M | ||
| Q3 25 | $47.2M | $-23.2M | ||
| Q2 25 | $25.0M | $7.4M | ||
| Q1 25 | $24.4M | $-28.7M | ||
| Q4 24 | $16.6M | $-25.7M | ||
| Q3 24 | $46.2M | $-12.2M | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
自由现金流率AMPHTGTX
| Q4 25 | 13.4% | 10.2% | ||
| Q3 25 | 24.6% | -14.4% | ||
| Q2 25 | 14.3% | 5.2% | ||
| Q1 25 | 14.3% | -23.8% | ||
| Q4 24 | 8.9% | -23.7% | ||
| Q3 24 | 24.1% | -14.6% | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
资本支出强度AMPHTGTX
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 5.1% | 0.0% |
现金转化率AMPHTGTX
| Q4 25 | 1.35× | 0.85× | ||
| Q3 25 | 3.03× | -0.06× | ||
| Q2 25 | 1.15× | 0.26× | ||
| Q1 25 | 1.39× | -5.67× | ||
| Q4 24 | 0.76× | -1.10× | ||
| Q3 24 | 1.48× | -3.15× | ||
| Q2 24 | 1.82× | 0.80× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TGTX
| Products | $189.1M | 98% |
| License | $3.5M | 2% |
